Preferred Label : Dupixent;
Origin ID : M000652138;
Related record
https://www.has-sante.fr/jcms/p_3473151/fr/dupixent-fasenra-nucala-tezspire-et-xolair-dans-le-traitement-de-l-asthme-severe
2023
France
guidelines for drug use
No Treatment for Diabetes
Nucala
Omalizumab
Borg Category-Ratio 10 Perceived Exertion Score 5
Omalizumab
Treat
tezspire
Treatment
Treatment Study
Severe Hallucination
Intensity and Distress 5
Severe Adverse Event
During Treatment
Epidermal cGVHD Score 4
Asthma
Dupilumab
asthma
Fasenra
Asthma Pathway
xolair
severe
Severe Dysplasia
asthma, nos
On Treatment
GDC Treatment Frequency Terminology
Treatment Epoch
Therapy Object
Dupixent
asthma
Biomaterial Treatment
Severe Extremity Pain
Mepolizumab
---
https://www.has-sante.fr/jcms/p_3345836/fr/dupixent-dupilumab-asthme-severe-de-l-enfant-age-de-6-a-11-ans
2022
France
evaluation of the transparency committee
dupilumab
Child
child, nos
asthma
Child
Child
due to
asthma, nos
age, nos
severe
Asthma
Child
dupilumab
Dupixent
asthma
child
---
https://www.has-sante.fr/upload/docs/application/pdf/2021-09/dupixent_06072021_avis_economique.pdf
2021
France
health technology assessment
Child
dermatitis
atopic dermatitis, nos
Atopic dermatitis
dupilumab
dupilumab
Dupixent
Child
child, nos
child
Child
Child
dermatitis, atopic
---
